1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies

STUDY OBJECTIVES

The objective of BCC in conducting this study is to provide an overview of the current and future characteristics of the global market for protein drugs/therapeutics. The key objective is to present a comprehensive analysis and future direction of protein drugs as an important tool in the treatment of various diseases.

This report explores present and future strategies within the protein therapeutics market, which includes peptide hormones, therapeutic enzymes, cytokines, monoclonal antibodies, blood factors, vaccines and peptide antibodies. The improvisation of the market, the setbacks and the needs of the market are discussed in this report. The classifications, manufacturing processes and usage of protein drugs are also portrayed.

A detailed analysis of protein therapeutics industry structure has been conducted. Revenues are broken down by region, by type and by manufacturing method. Sales figures are given for 2011, 2012 and estimated for the five-year period from 2013 through 2018.
The report also covers significant patents and their allotments in each category.

REASONS FOR DOING THIS STUDY

Widespread research in the field of protein therapeutics has discovered specific functionality that provides therapeutic treatments for various diseases.
R&D spending, along with increasing competition, patent expiries and new technologies are providing a new direction. New advancements, new product launches and a changing lifestyle have caused the market to grow in the foreseeable future. This study looks at almost all the systems affected by these factors.

Acquisition strategies and collaborations by companies are also covered in this report. This study also discusses the strength and weaknesses of each type of technology in light of the new technologies, growing competition, and changing customer needs.

INTENDED AUDIENCE

This study contributes to the areas of market growth in protein therapeutics manufacturers and users. Pharmaceutical biotechnical companies, research institutes, and physicians will find this study to be of interest.

SCOPE OF THE STUDY

The scope of this study encompasses protein therapeutics in pharmaceutical and biotechnology markets. BCC Research analyzes each market and its applications, regulatory environment, technology, market projections, and market shares. Technological issues include the latest trends and developments. The emerging market for enzyme inhibitors includes countries like India, China, Japan, Korea, Taiwan, Africa, Australia, New Zealand, etc.

METHODOLOGY

Both primary and secondary research methodologies were used in preparing this study. BCC Research conducted a comprehensive literature search, which included technical newsletters and journals, and many other sources. Data were collected through interviews and correspondence with manufacturers of enzyme inhibitors and technical experts. Projections were based on estimates such as the current number of end users, potential end users, mergers and acquisitions, and market trends.

INFORMATION SOURCES

Many companies were surveyed to obtain data for this study. Included were manufacturers and end users of kinase inhibitors in therapeutic categories and various disease sectors industries. Data were gathered from various industry sources. BCC Research spoke with officials within the industry, consulted newsletters, company literature, product literature, and a host of technical articles, journals, indexes, and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, data were compiled from current financial, trade, and government sources.

ABOUT THE AUTHOR

A team of professionals in the biotechnology industry carried out this study. The project manager is Shalini S Dewan, who holds a master’s degree in pharmaceutical chemistry and has over 14 years of industry experience. Among the research topics she has covered are studies on compounds of potential pharmaceutical interest from ibuprofen and 2-naphthyl acetic acid. Shalini was awarded a Gold Medal by the Prime Minister of India for her work and has worked with top companies in India and in the U.S. Some of her other reports with BCC Research are:
• Reagents of Chromatography; Spectroscopy, an Enduring Market; Advanced Drug Delivery Systems.
• Orthopedic Drugs, Implants and Devices.
• Imaging Reagents; Regulatory Industry.
• Dynamic Sera, Media and Reagents Used in Biotechnology.
• Contract Pharmaceutical Manufacturing, Research and Packaging.
• Chiral Technology: Global Markets.
• Autacoids and Related Drugs.
• Contraceptives.
• Liver Disease Treatments.
• The Global Market, Hormone Replacement Therapies and Other Hormone Therapies.
• Global Markets, Cardiovascular Medicine: Diagnostics, Drugs and Devices.
• Cancer Therapies: Technologies and Global Market;
• Medical Imaging Reagents and Analysis Equipment.

The lead consultant for this project was Dr. Kapil A Setia, who holds a doctoral degree in life sciences. He has a number of research publications to his credit, including his thesis, which was given an award of excellence.

REPORT HIGHLIGHTS

This report will provide:
• An overview of the markets for major classes of protein with a focus on cytokines and monoclonal antibodies
• Analyses of market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018
• Examinations of current successes, including size and sales forecasts for this segment over the next five years
• Discussion of the regulatory environment, technological developments and their related strengths and weaknesses, as well as discussion on growing competition and changing customer needs.

Table Of Contents

Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies
TABLE OF CONTENTS
CHAPTER 1 INTRODUCTION 2
STUDY OBJECTIVES 2
REASONS FOR DOING THIS STUDY 2
INTENDED AUDIENCE 2
SCOPE OF THE STUDY 2
METHODOLOGY 3
INFORMATION SOURCES 3
ABOUT THE AUTHOR 3
RELATED BCC RESEARCH REPORTS 4
BCC ONLINE SERVICES 4
DISCLAIMER 4
CHAPTER 2 SUMMARY 6
SUMMARY TABLE GLOBAL REVENUE OF PROTEIN THERAPEUTICS MARKET,
THROUGH 2018 ($ MILLIONS) 6
SUMMARY FIGURE GLOBAL REVENUE OF PROTEIN THERAPEUTICS MARKET,
2011-2018 ($ MILLIONS) 7
CHAPTER 3 OVERVIEW 9
DEFINITIONS 9
HISTORY 9
TABLE 1 EVOLUTION OF THERAPEUTIC PROTEINS 10
PHARMACOLOGICAL CLASSIFICATION OF THERAPEUTIC PROTEINS 11
PROTEIN THERAPEUTICS WITH ENZYMATIC OR REGULATORY ACTIVITY 11
PROTEIN THERAPEUTICS WITH SPECIAL TARGETED ACTIVITY 12
PROTEIN VACCINES 12
MANUFACTURING TECHNOLOGIES 12
NATURAL SOURCING AND EXTRACTION 13
TABLE 2 PROTEIN DRUGS MADE BY HUMAN SOURCE EXTRACTION 13
TABLE 3 PROTEIN DRUGS MADE BY ANIMAL SOURCE EXTRACTION 14
MICROBIAL FERMENTATION 15
TABLE 4 PROTEIN DRUGS MADE BY MICROBIAL FERMENTATION 16
TRANSGENICS 16
TABLE 5 PROTEIN DRUGS MADE BY TRANSGENIC ORGANISMS 17
MAMMALIAN CELL CULTURE 17
TABLE 6 PROTEIN DRUGS MADE BY MAMMALIAN CELL CULTURE 18
OTHER CELL CULTURE SYSTEMS 18
TABLE 7 PROTEIN DRUGS MADE BY INSECT CELL CULTURE 18
MOLECULAR CLASSIFICATION OF THERAPEUTIC PROTEINS 18
CYTOKINES 19
Colony-stimulating Factors 19
Interferons 19
Interleukins 20
ANTIBODIES 20
BLOOD PRODUCTS 21
Alpha-1- Proteinase Inhibitor 21
BIO133A - Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and
Monoclonal Antibodies
Copyright © BCC Research, Wellesley MA USA, Website: www.bccresearch.com
TOPIC PAGE NO.
Antihemophilic Factor 21
Antithrombin 22
C1 Esterase Inhibitor 22
Coagulation Factors 23
Immuno-Globulins 23
Protein C 24
Thrombin 24
PEPTIDE ANTIBIOTICS 25
VACCINES 25
ENZYMES 26
Digestive Enzymes 27
Lysosomal Enzymes 27
Thrombolytic Enzymes 28
Other Enzymes 28
PEPTIDE HORMONES 28
Follicle-stimulating Hormone and Luteinizing Hormone 29
Adrenocorticotropic Hormone 29
Growth Hormones 29
Erythropoietin 29
Insulin 30
CHAPTER 4 REGULATORY ASPECTS 32
MONOCLONAL ANTIBODIES 32
TABLE 8 NEW APPROVALS OF MONOCLONAL ANTIBODIES (2009-JUNE 2013) 32
THERAPEUTIC ENZYMES 34
TABLE 9 NEW APPROVALS OF THERAPEUTIC ENZYMES (2009-JUNE 2013) 34
CYTOKINES 35
TABLE 10 NEW APPROVALS OF CYTOKINES (2009-JUNE 2013) 36
VACCINES 36
TABLE 11 NEW APPROVALS OF VACCINES (2009-JUNE 2013) 36
BLOOD FACTORS 39
TABLE 12 NEW APPROVALS OF BLOOD FACTORS (2009-JUNE 2013) 39
PEPTIDE HORMONES 42
TABLE 13 NEW APPROVALS OF PEPTIDE HORMONES (2009- JUNE 2013) 42
NEW DRUG APPLICATIONS/BIOLOGICAL LICENSE APPLICATIONS 42
TABLE 14 NEW DRUG APPLICATIONS/BIOLOGICAL LICENSE APPLICATIONS
(2009-JUNE 2013) 43
RECALLS 44
TABLE 15 RECALLS (2009-JUNE 2013) 45
SAFETY ALERTS 48
TABLE 16 SAFETY ALERTS (2009-JUNE 2013) 49
CHAPTER 5 NEW DEVELOPMENTS 52
BLOOD PRODUCTS 52
TABLE 17 NEW DEVELOPMENTS/CLINICAL TRIALS IN BLOOD PRODUCTS 53
VACCINES 55
TABLE 18 NEW DEVELOPMENTS/CLINICAL TRIALS IN VACCINES 55
PEPTIDE HORMONES 58
BIO133A - Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and
Monoclonal Antibodies
Copyright © BCC Research, Wellesley MA USA, Website: www.bccresearch.com
TOPIC PAGE NO.
TABLE 19 NEW DEVELOPMENTS/CLINICAL TRIALS IN PEPTIDE HORMONES 58
PEPTIDE ANTIBIOTICS 60
TABLE 20 NEW DEVELOPMENTS/CLINICAL TRIALS IN PEPTIDE ANTIBIOTICS 61
CYTOKINES 62
TABLE 21 NEW DEVELOPMENTS/CLINICAL TRIALS IN CYTOKINES 63
MONOCLONAL ANTIBODIES 64
TABLE 22 NEW DEVELOPMENTS/CLINICAL TRIALS IN MONOCLONAL ANTIBODIES 65
THERAPEUTIC ENZYMES 70
TABLE 23 NEW DEVELOPMENTS/CLINICAL TRIALS IN ENZYMES 71
CHAPTER 6 GLOBAL MARKETS 73
MARKETS BY TYPE 74
MARKET OVERVIEW 75
MARKET REVENUE 79
TABLE 24 GLOBAL MARKET FOR PROTEIN THERAPEUTICS BY TYPE, THROUGH 2018
($ MILLIONS) 79
FIGURE 1 GLOBAL MARKET FOR PROTEIN THERAPEUTICS, BY TYPE, THROUGH 2018
($ MILLIONS) 79
MARKET SHARE 80
TABLE 25 MARKET SHARE OF PROTEIN THERAPEUTICS, BY TYPE, 2012 (%) 80
FIGURE 2 MARKET SHARE OF PROTEIN THERAPEUTICS, BY TYPE, 2012 (%) 80
MARKET BY REGION 81
MARKET OVERVIEW 82
MARKET REVENUE 84
TABLE 26 GLOBAL MARKET FOR PROTEIN THERAPEUTICS BY REGION, THROUGH
2018 ($ MILLIONS) 84
FIGURE 3 GLOBAL MARKET FOR PROTEIN THERAPEUTICS BY REGION, 2011-2018 ($
MILLIONS) 84
MARKET SHARE 85
TABLE 27 MARKET SHARE OF PROTEIN THERAPEUTICS, BY REGION, 2012 (%) 85
FIGURE 4 MARKET SHARE OF PROTEIN THERAPEUTICS, BY REGION, 2012 (%) 85
MARKET FOR PEPTIDE HORMONES AND THERAPEUTIC ENZYMES 85
Market Overview 86
Market Revenue 86
TABLE 28 GLOBAL MARKET FOR PEPTIDE HORMONES AND THERAPEUTIC ENZYMES
BY REGION, THROUGH 2018 ($ MILLIONS) 87
FIGURE 5 GLOBAL MARKET FOR PEPTIDE HORMONES AND THERAPEUTIC ENZYMES
BY REGION, 2011-2018 ($ MILLIONS) 87
Market Share 87
TABLE 29 MARKET SHARE OF PEPTIDE HORMONES AND THERAPEUTIC ENZYMES
BY REGION, 2012 (%) 88
FIGURE 6 MARKET SHARE OF PEPTIDE HORMONES AND THERAPEUTIC ENZYMES BY
REGION, 2012 (%) 88
MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES 88
Market Overview 89
Market Revenue 89
TABLE 30 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY
REGION, THROUGH 2018 ($ MILLIONS) 90
BIO133A - Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and
Monoclonal Antibodies
Copyright © BCC Research, Wellesley MA USA, Website: www.bccresearch.com
TOPIC PAGE NO.
FIGURE 7 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY
REGION, 2011-2018 ($ MILLIONS) 90
Market Share 91
TABLE 31 MARKET SHARE OF MONOCLONAL ANTIBODIES BY REGION, 2012 (%) 91
FIGURE 8 MARKET SHARE OF MONOCLONAL ANTIBODIES BY REGION, 2012 (%) 91
MARKET FOR BLOOD FACTORS, VACCINES AND PEPTIDE ANTIBIOTICS 91
Market Overview 92
Market Revenue 93
TABLE 32 GLOBAL MARKET FOR BLOOD FACTORS, VACCINES AND PEPTIDE
ANTIBIOTICS BY REGION, THROUGH 2018 ($ MILLIONS) 93
FIGURE 9 GLOBAL MARKET FOR BLOOD FACTORS, VACCINES AND PEPTIDE
ANTIBIOTICS BY REGION, 2011-2018 ($ MILLIONS) 93
Market Share 94
TABLE 33 MARKET SHARE OF BLOOD FACTORS, VACCINES AND PEPTIDE
ANTIBIOTICS BY REGION, 2012 (%) 94
FIGURE 10 MARKET SHARE OF BLOOD FACTORS, VACCINES AND PEPTIDE
ANTIBIOTICS BY REGION, 2012 (%) 94
MARKET BY MANUFACTURING PROCESS 95
MARKET OVERVIEW 97
MARKET REVENUE 99
TABLE 34 GLOBAL MARKET FOR PROTEIN THERAPEUTICS BY TYPES OF
MANUFACTURING PROCESSES, THROUGH 2018 ($ MILLIONS) 99
FIGURE 11 GLOBAL MARKET FOR PROTEIN THERAPEUTICS BY TYPES OF
MANUFACTURING PROCESSES, 2011-2018 ($ MILLIONS) 100
MARKET SHARE 100
TABLE 35 MARKET SHARE OF PROTEIN THERAPEUTICS BY TYPE OF
MANUFACTURING PROCESS, 2012 (%) 100
FIGURE 12 MARKET SHARE OF PROTEIN THERAPEUTICS BY TYPE OF
MANUFACTURING PROCESS, 2012 (%) 101
CHAPTER 7 CYTOKINES AND MONOCLONAL ANTIBODIES 103
MARKET BY TYPE 103
MARKET OVERVIEW 103
MARKET REVENUE 104
TABLE 36 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY
REGION, THROUGH 2018 ($ MILLIONS) 105
FIGURE 13 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY
REGION, 2011-2018 ($ MILLIONS) 105
MARKET SHARE 106
TABLE 37 MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012
(%) 106
FIGURE 14 MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012
(%) 106
CYTOKINES MARKET 106
Market Overview 107
Market Revenue 107
TABLE 38 GLOBAL MARKET FOR CYTOKINES BY TYPE, THROUGH 2018 ($ MILLIONS) 108
FIGURE 15 GLOBAL MARKET FOR CYTOKINES BY TYPE, 2011-2018 ($ MILLIONS) 108
Market Share 109
TABLE 39 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) 109
BIO133A - Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and
Monoclonal Antibodies
Copyright © BCC Research, Wellesley MA USA, Website: www.bccresearch.com
TOPIC PAGE NO.
FIGURE 16 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) 109
MONOCLONAL ANTIBODIES MARKET 109
Market Overview 110
Market Revenue 110
TABLE 40 GLOBAL MARKET FOR MONOCLONAL ANTIBODIES BY TYPE, THROUGH
2018 ($ MILLIONS) 111
FIGURE 17 GLOBAL MARKET FOR MONOCLONAL ANTIBODIES BY TYPE, 2011-2018
($ MILLIONS) 111
Market Share 111
TABLE 41 MARKET SHARE OF MONOCLONAL ANTIBODIES BY TYPE, 2012 (%) 112
FIGURE 18 MARKET SHARE OF MONOCLONAL ANTIBODIES BY TYPE, 2012 (%) 112
MARKET BY REGION 112
CYTOKINES 113
Market Overview 113
Market Revenue 114
TABLE 42 GLOBAL MARKET FOR CYTOKINES BY REGION, THROUGH 2018 ($
MILLIONS) 114
FIGURE 19 GLOBAL MARKET FOR CYTOKINES BY REGION, 2011-2018 ($ MILLIONS) 114
Market Share 115
TABLE 43 MARKET SHARE OF CYTOKINES BY REGION, 2012 (%) 115
FIGURE 20 MARKET SHARE OF CYTOKINES BY REGION, 2012 (%) 115
MONOCLONAL ANTIBODIES 115
Market Overview 116
Market Revenue 117
TABLE 44 GLOBAL MARKET FOR MONOCLONAL ANTIBODIES BY REGION, THROUGH
2018 ($ MILLIONS) 117
FIGURE 21 GLOBAL MARKET FOR MONOCLONAL ANTIBODIES BY REGION,
2011-2018 ($ MILLIONS) 117
Market Share 118
TABLE 45 MARKET SHARE OF MONOCLONAL ANTIBODIES BY REGION, 2012 (%) 118
FIGURE 22 MARKET SHARE OF MONOCLONAL ANTIBODIES BY REGION, 2012 (%) 118
MARKET BY MANUFACTURING PROCESS 118
CYTOKINES 119
Market Overview 119
Market Revenue 119
TABLE 46 GLOBAL MARKET FOR CYTOKINES BY TYPES OF MANUFACTURING
PROCESSES, THROUGH 2018 ($ MILLIONS) 120
FIGURE 23 GLOBAL MARKET FOR CYTOKINES BY TYPES OF MANUFACTURING
PROCESSES, 2011-2018 (%) 120
Market Share 120
TABLE 47 MARKET SHARE OF CYTOKINES, BY TYPE OF MANUFACTURING
PROCESSES, 2012 (%) 121
FIGURE 24 MARKET SHARE OF CYTOKINES, BY TYPE OF MANUFACTURING
PROCESSES, 2012 (%) 121
MONOCLONAL ANTOBODIES 121
Market Overview 121
Market Revenue 122
TABLE 48 GLOBAL MARKET FOR MONOCLONAL ANTIBODIES BY TYPES OF
MANUFACTURING PROCESSES, THROUGH 2018 ($ MILLIONS) 122
BIO133A - Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and
Monoclonal Antibodies
Copyright © BCC Research, Wellesley MA USA, Website: www.bccresearch.com
TOPIC PAGE NO.
FIGURE 25 GLOBAL MARKET FOR MONOCLONAL ANTIBODIES BY TYPES OF
MANUFACTURING PROCESSES, 2011-2018 ($ MILLIONS) 122
Market Share 123
TABLE 49 MARKET SHARE OF MONOCLONAL ANTOBODIES BY TYPE OF
MANUFACTURING PROCESSES, 2012 (%) 123
FIGURE 26 MARKET SHARE OF MONOCLONAL ANTOBODIES BY TYPE OF
MANUFACTURING PROCESSES, 2012 (%) 123
INDUSTRY STRUCTURE 124
CYTOKINES 124
Market Leaders 124
TABLE 50 GLOBAL MANUFACTURERS OF CYTOKINES 124
Market Share 125
TABLE 51 MARKET SHARE OF CYTOKINES MANUFACTURING COMPANIES, 2012 (%) 125
FIGURE 27 MARKET SHARE OF CYTOKINES MANUFACTURING COMPANIES, 2012 (%) 125
MONOCLONAL ANTIBODIES 126
Market Leader 126
TABLE 52 GLOBAL MANUFACTURERS OF MONOCLONAL ANTIBODIES 126
Market Share 127
TABLE 53 MARKET SHARE OF MONOCLONAL ANTIBODIES MANUFACTURING
COMPANIES, 2012 (%) 128
FIGURE 28 MARKET SHARE OF MONOCLONAL ANTIBODIES MANUFACTURING
COMPANIES, 2012 (%) 128
CHAPTER 8 PATENT ANALYSIS 130
PATENTS BY YEAR 130
TABLE 54 NUMBER OF SIGNIFICANT PATENTS, BY YEAR, JANUARY 2009-JUNE 2013 130
FIGURE 29 NUMBER OF SIGNIFICANT PATENTS, BY YEAR, JANUARY 2009-JUNE 2013 130
PATENTS BY TYPE/CATEGORY 131
TABLE 55 PATENTS BY CATEGORY, JANUARY 2009-JUNE 2013 131
FIGURE 30 PATENTS BY CATEGORY, JANUARY 2009-JUNE 2013 131
PATENTS BY COMPANY 132
TABLE 56 NUMBER OF U.S. PATENTS, BY COMPANY, JANUARY 2009- JUNE 2013 132
PATENTS BY COUNTRY 137
TABLE 57 NUMBER OF U.S. PATENTS, BY COUNTRY, JANUARY 2009-JUNE 2013 137
TABLE 58 PATENT SHARES, BY COUNTRY, JANUARY 2009-JUNE 2013 (%) 138
PATENTS BY ASSIGNEE 139
TABLE 59 NUMBER OF PATENTS BY ASSIGNEE, JANUARY 2009-JUNE 2013 139
FIGURE 31 NUMBER OF PATENTS BY ASSIGNEE, JANUARY 2009-JUNE 2013 139
CHAPTER 9 CURRENT SITUATION 141
FACTORS AFFECTING THE PROTEIN THERAPEUTICS MARKET 141
INCREASING PREVALENCE OF CHRONIC DISEASES 141
GROWING AGING POPULATION 141
LIFESTYLE CHANGES 142
NEW PRODUCT LAUNCHES 142
ADVANCEMENTS IN MANUFACTURING TECHNOLOGIES 142
PRICE CONTROLS 143
REGULATORY PRESSURES 143
ENTRY OF FOLLOW-ON-BIOLOGICS/BIOSIMILARS 143
MERGERS AND ACQUISITIONS 144
LICENSING AGREEMENTS 144

CHAPTER 10 COMPANY PROFILES 146

ABBOTT LABORATORIES 146
AFFYMAX 146
ALCON 147
ALEXION PHARMACEUTICALS 147
ALLERGAN INC 148
AMGEN 148
BAXTER HEALTHCARE 149
BAYER HEALTHCARE PHARMACEUTICALS 149
BIO PRODUCTS LABORATORY 150
BIOGEN IDEC 150
BIOTEST PHARMACEUTICALS CORPORATION 151
BOEHRINGER INGELHEIM 151
BRISTOL-MYERS SQUIBB 152
BTG INTERNATIONAL LIMITED 152
CANGENE CORPORATION 153
CSL LIMITED 153
DENDREON COPORATION 154
EISAI CO. LTD. 154
ELI LILLY 155
FERRING PHARMACEUTICALS 156
FRESENIUS KABI USA 156
GLAXOSMITHKLINE 157
GRIFOLS BIOLOGICALS INC 157
HOFFMAN-LA-ROCHE 158
HOSPIRA 158
JANSSEN-CILAG 158
JOHNSON and JOHNSON 159
KAMADA LTD. 160
KEDRION BIOPHARMACEUTICALS, SPA 160
LUNDBECK LLC 161
MEDIMMUNE LLC 161
MERCK and CO, INC 161
MERCK KGAA 162
MYLAN INC. 163
NABI BIOPHARMACEUTICALS (NOW BIOTA PHARMACEUTICALS) 163
NOVARTIS 164
NOVO NORDISK INC 165
OCTAPHARMA PHARMAZEUTIKA PRODUKTIONSGES.M.B.H 165
OMRIX BIOPHARMACEUTICALS LTD 166
PFIZER INC 166
PROTEIN SCIENCES CORPORATION 167
RARE DISEASE THERAPEUTICS INC. 167
REVO BIOLOGICS 168
SANDOZ 168
SANOFI 169
SEATTLE GENETICS INC. 169
SPECTRUM PHARMACEUTICALS INC. 170
TAKEDA PHARMACEUTICALS 170
UCB COMPANY 171
UPSHER SMITH LABORATORIES INC 171
VIROPHARMA INC 172
WATSON LABS 172
WOCKHARDT LIMITED 173
X-GEN PHARMS 173
ZYMOGENETICS, INC 173

CHAPTER 11 APPENDIX: ABBREVIATIONS 176



LIST OF TABLES

SUMMARY TABLE GLOBAL REVENUE OF PROTEIN THERAPEUTICS MARKET, THROUGH
2018 ($ MILLIONS) 6
TABLE 1 EVOLUTION OF THERAPEUTIC PROTEINS 10
TABLE 2 PROTEIN DRUGS MADE BY HUMAN SOURCE EXTRACTION 13
TABLE 3 PROTEIN DRUGS MADE BY ANIMAL SOURCE EXTRACTION 14
TABLE 4 PROTEIN DRUGS MADE BY MICROBIAL FERMENTATION 16
TABLE 5 PROTEIN DRUGS MADE BY TRANSGENIC ORGANISMS 17
TABLE 6 PROTEIN DRUGS MADE BY MAMMALIAN CELL CULTURE 18
TABLE 7 PROTEIN DRUGS MADE BY INSECT CELL CULTURE 18
TABLE 8 NEW APPROVALS OF MONOCLONAL ANTIBODIES (2009-JUNE 2013) 32
TABLE 9 NEW APPROVALS OF THERAPEUTIC ENZYMES (2009-JUNE 2013) 34
TABLE 10 NEW APPROVALS OF CYTOKINES (2009-JUNE 2013) 36
TABLE 11 NEW APPROVALS OF VACCINES (2009-JUNE 2013) 36
TABLE 12 NEW APPROVALS OF BLOOD FACTORS (2009-JUNE 2013) 39
TABLE 13 NEW APPROVALS OF PEPTIDE HORMONES (2009- JUNE 2013) 42
TABLE 14 NEW DRUG APPLICATIONS/BIOLOGICAL LICENSE APPLICATIONS
(2009-JUNE 2013) 43
TABLE 15 RECALLS (2009-JUNE 2013) 45
TABLE 16 SAFETY ALERTS (2009-JUNE 2013) 49
TABLE 17 NEW DEVELOPMENTS/CLINICAL TRIALS IN BLOOD PRODUCTS 53
TABLE 18 NEW DEVELOPMENTS/CLINICAL TRIALS IN VACCINES 55
TABLE 19 NEW DEVELOPMENTS/CLINICAL TRIALS IN PEPTIDE HORMONES 58
TABLE 20 NEW DEVELOPMENTS/CLINICAL TRIALS IN PEPTIDE ANTIBIOTICS 61
TABLE 21 NEW DEVELOPMENTS/CLINICAL TRIALS IN CYTOKINES 63
TABLE 22 NEW DEVELOPMENTS/CLINICAL TRIALS IN MONOCLONAL ANTIBODIES 65
TABLE 23 NEW DEVELOPMENTS/CLINICAL TRIALS IN ENZYMES 71
TABLE 24 GLOBAL MARKET FOR PROTEIN THERAPEUTICS BY TYPE, THROUGH 2018
($ MILLIONS) 79
TABLE 25 MARKET SHARE OF PROTEIN THERAPEUTICS, BY TYPE, 2012 (%) 80
TABLE 26 GLOBAL MARKET FOR PROTEIN THERAPEUTICS BY REGION, THROUGH
2018 ($ MILLIONS) 84
TABLE 27 MARKET SHARE OF PROTEIN THERAPEUTICS, BY REGION, 2012 (%) 85
TABLE 28 GLOBAL MARKET FOR PEPTIDE HORMONES AND THERAPEUTIC ENZYMES
BY REGION, THROUGH 2018 ($ MILLIONS) 87
TABLE 29 MARKET SHARE OF PEPTIDE HORMONES AND THERAPEUTIC ENZYMES BY
REGION, 2012 (%) 88
TABLE 30 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY
REGION, THROUGH 2018 ($ MILLIONS) 90
TABLE 31 MARKET SHARE OF MONOCLONAL ANTIBODIES BY REGION, 2012 (%) 91
TABLE 32 GLOBAL MARKET FOR BLOOD FACTORS, VACCINES AND PEPTIDE
ANTIBIOTICS BY REGION, THROUGH 2018 ($ MILLIONS) 93
TABLE 33 MARKET SHARE OF BLOOD FACTORS, VACCINES AND PEPTIDE
ANTIBIOTICS BY REGION, 2012 (%) 94
TABLE 34 GLOBAL MARKET FOR PROTEIN THERAPEUTICS BY TYPES OF
MANUFACTURING PROCESSES, THROUGH 2018 ($ MILLIONS) 99
TABLE 35 MARKET SHARE OF PROTEIN THERAPEUTICS BY TYPE OF MANUFACTURING
PROCESS, 2012 (%) 100
TABLE 36 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY
REGION, THROUGH 2018 ($ MILLIONS) 105
TABLE 37 MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) 106
TABLE 38 GLOBAL MARKET FOR CYTOKINES BY TYPE, THROUGH 2018 ($ MILLIONS) 108
TABLE 39 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) 109
TABLE 40 GLOBAL MARKET FOR MONOCLONAL ANTIBODIES BY TYPE, THROUGH
2018 ($ MILLIONS) 111
TABLE 41 MARKET SHARE OF MONOCLONAL ANTIBODIES BY TYPE, 2012 (%) 112
TABLE 42 GLOBAL MARKET FOR CYTOKINES BY REGION, THROUGH 2018 ($
MILLIONS) 114
TABLE 43 MARKET SHARE OF CYTOKINES BY REGION, 2012 (%) 115
TABLE 44 GLOBAL MARKET FOR MONOCLONAL ANTIBODIES BY REGION, THROUGH
2018 ($ MILLIONS) 117
TABLE 45 MARKET SHARE OF MONOCLONAL ANTIBODIES BY REGION, 2012 (%) 118
TABLE 46 GLOBAL MARKET FOR CYTOKINES BY TYPES OF MANUFACTURING
PROCESSES, THROUGH 2018 ($ MILLIONS) 120
TABLE 47 MARKET SHARE OF CYTOKINES, BY TYPE OF MANUFACTURING PROCESSES,
2012 (%) 121
TABLE 48 GLOBAL MARKET FOR MONOCLONAL ANTIBODIES BY TYPES OF
MANUFACTURING PROCESSES, THROUGH 2018 ($ MILLIONS) 122
TABLE 49 MARKET SHARE OF MONOCLONAL ANTOBODIES BY TYPE OF
MANUFACTURING PROCESSES, 2012 (%) 123
TABLE 50 GLOBAL MANUFACTURERS OF CYTOKINES 124
TABLE 51 MARKET SHARE OF CYTOKINES MANUFACTURING COMPANIES, 2012 (%) 125
TABLE 52 GLOBAL MANUFACTURERS OF MONOCLONAL ANTIBODIES 126
TABLE 53 MARKET SHARE OF MONOCLONAL ANTIBODIES MANUFACTURING
COMPANIES, 2012 (%) 128
TABLE 54 NUMBER OF SIGNIFICANT PATENTS, BY YEAR, JANUARY 2009-JUNE 2013 130
TABLE 55 PATENTS BY CATEGORY, JANUARY 2009-JUNE 2013 131
TABLE 56 NUMBER OF U.S. PATENTS, BY COMPANY, JANUARY 2009- JUNE 2013 132
TABLE 57 NUMBER OF U.S. PATENTS, BY COUNTRY, JANUARY 2009-JUNE 2013 137
TABLE 58 PATENT SHARES, BY COUNTRY, JANUARY 2009-JUNE 2013 (%) 138
TABLE 59 NUMBER OF PATENTS BY ASSIGNEE, JANUARY 2009-JUNE 2013 139



LIST OF FIGURES

SUMMARY FIGURE GLOBAL REVENUE OF PROTEIN THERAPEUTICS MARKET,
2011-2018 ($ MILLIONS) 7
FIGURE 1 GLOBAL MARKET FOR PROTEIN THERAPEUTICS, BY TYPE, THROUGH 2018
($ MILLIONS) 79
FIGURE 2 MARKET SHARE OF PROTEIN THERAPEUTICS, BY TYPE, 2012 (%) 80
FIGURE 3 GLOBAL MARKET FOR PROTEIN THERAPEUTICS BY REGION, 2011-2018 ($
MILLIONS) 84
FIGURE 4 MARKET SHARE OF PROTEIN THERAPEUTICS, BY REGION, 2012 (%) 85
FIGURE 5 GLOBAL MARKET FOR PEPTIDE HORMONES AND THERAPEUTIC ENZYMES
BY REGION, 2011-2018 ($ MILLIONS) 87
FIGURE 6 MARKET SHARE OF PEPTIDE HORMONES AND THERAPEUTIC ENZYMES BY
REGION, 2012 (%) 88
FIGURE 7 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY
REGION, 2011-2018 ($ MILLIONS) 90
FIGURE 8 MARKET SHARE OF MONOCLONAL ANTIBODIES BY REGION, 2012 (%) 91
FIGURE 9 GLOBAL MARKET FOR BLOOD FACTORS, VACCINES AND PEPTIDE
ANTIBIOTICS BY REGION, 2011-2018 ($ MILLIONS) 93
FIGURE 10 MARKET SHARE OF BLOOD FACTORS, VACCINES AND PEPTIDE
ANTIBIOTICS BY REGION, 2012 (%) 94
FIGURE 11 GLOBAL MARKET FOR PROTEIN THERAPEUTICS BY TYPES OF
MANUFACTURING PROCESSES, 2011-2018 ($ MILLIONS) 100
FIGURE 12 MARKET SHARE OF PROTEIN THERAPEUTICS BY TYPE OF
MANUFACTURING PROCESS, 2012 (%) 101
FIGURE 13 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY
REGION, 2011-2018 ($ MILLIONS) 105
FIGURE 14 MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012
(%) 106
FIGURE 15 GLOBAL MARKET FOR CYTOKINES BY TYPE, 2011-2018 ($ MILLIONS) 108
FIGURE 16 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) 109
FIGURE 17 GLOBAL MARKET FOR MONOCLONAL ANTIBODIES BY TYPE, 2011-2018 ($
MILLIONS) 111
FIGURE 18 MARKET SHARE OF MONOCLONAL ANTIBODIES BY TYPE, 2012 (%) 112
FIGURE 19 GLOBAL MARKET FOR CYTOKINES BY REGION, 2011-2018 ($ MILLIONS) 114
FIGURE 20 MARKET SHARE OF CYTOKINES BY REGION, 2012 (%) 115
FIGURE 21 GLOBAL MARKET FOR MONOCLONAL ANTIBODIES BY REGION, 2011-2018
($ MILLIONS) 117
FIGURE 22 MARKET SHARE OF MONOCLONAL ANTIBODIES BY REGION, 2012 (%) 118
FIGURE 23 GLOBAL MARKET FOR CYTOKINES BY TYPES OF MANUFACTURING
PROCESSES, 2011-2018 (%) 120
FIGURE 24 MARKET SHARE OF CYTOKINES, BY TYPE OF MANUFACTURING
PROCESSES, 2012 (%) 121
FIGURE 25 GLOBAL MARKET FOR MONOCLONAL ANTIBODIES BY TYPES OF
MANUFACTURING PROCESSES, 2011-2018 ($ MILLIONS) 122
FIGURE 26 MARKET SHARE OF MONOCLONAL ANTOBODIES BY TYPE OF
MANUFACTURING PROCESSES, 2012 (%) 123
FIGURE 27 MARKET SHARE OF CYTOKINES MANUFACTURING COMPANIES, 2012 (%) 125
FIGURE 28 MARKET SHARE OF MONOCLONAL ANTIBODIES MANUFACTURING
COMPANIES, 2012 (%) 128
FIGURE 29 NUMBER OF SIGNIFICANT PATENTS, BY YEAR, JANUARY 2009-JUNE 2013 130
FIGURE 30 PATENTS BY CATEGORY, JANUARY 2009-JUNE 2013 131
FIGURE 31 NUMBER OF PATENTS BY ASSIGNEE, JANUARY 2009-JUNE 2013 139

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Monoclonal Antibodies (mAbs) Market Analysis By Source (Chimeric, Murine, Humanized, Human), By Type of Production, By Indication (Cancer, Autoimmune, Inflammatory, Infectious, Microbial, Viral Diseases), By End-use And Segment Forecasts, 2013 - 2024

Monoclonal Antibodies (mAbs) Market Analysis By Source (Chimeric, Murine, Humanized, Human), By Type of Production, By Indication (Cancer, Autoimmune, Inflammatory, Infectious, Microbial, Viral Diseases), By End-use And Segment Forecasts, 2013 - 2024

  • $ 4950
  • Industry report
  • November 2016
  • by Grand View Research

The global monoclonal antibodies (mAbs) market was valued at USD 85.4 billion in 2015 and is expected to reach a value of USD 138.6 billion by 2024. Increasing R&D pertaining to the development of therapeutic ...

Global and Chinese Monoclonal Antibody Diagnostic Reagents Industry, 2016 Market Research Report

Global and Chinese Monoclonal Antibody Diagnostic Reagents Industry, 2016 Market Research Report

  • $ 3000
  • Industry report
  • November 2016
  • by Prof Research

The ’Global and Chinese Monoclonal Antibody Diagnostic Reagents Industry, 2011-2021 Market Research Report’ is a professional and in-depth study on the current state of the global Monoclonal Antibody ...

Global Antibody Partnering Terms and Agreements 2010-2016: Deal trends, players and financials

Global Antibody Partnering Terms and Agreements 2010-2016: Deal trends, players and financials

  • $ 2995
  • Industry report
  • November 2016
  • by Currentpartnering

The Global Antibody Partnering Terms and Agreements 2010 to 2016 report provides comprehensive understanding and unprecedented access to the Antibody partnering deals and agreements entered into by the ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.